<DOC>
	<DOCNO>NCT00222469</DOCNO>
	<brief_summary>The purpose study find give patient bevacizumab along chemotherapy drug oxaliplatin gemcitabine improve overall survival . In addition , study find side effect patient may take bevacizumab , oxaliplatin , gemcitabine together .</brief_summary>
	<brief_title>Combination Chemotherapy 1st Line Treatment Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Design : - A phase II single arm study . All patient receive bevacizumab 10mg/kg gemcitabine 1000mg/m2 day 1 follow oxaliplatin 100mg/m2 day 2 14 day cycle . Purpose : - The purpose study find give patient bevacizumab , along chemotherapy drug oxaliplatin gemcitabine , improve overall survival . In addition , study find side effect patient may take bevacizumab , oxaliplatin gemcitabine together . Enrollment : - Approximately 30 patient enrol study University Oklahoma M.D . Anderson Cancer Center . Duration : - The study conduct approximately 2 year .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; /= 18 year old ECOG performance status 02 . Patients metastatic unresectable locally advanced adenocarcinoma pancreas . Patients recurrent disease post pancreaticoduodenectomy earlier 6 month resection . Patients recurrent disease complete adjuvant therapy form radiation without radiosensitizing 5fluorouracil ( 5FU ) 6 month prior recurrence may include . Signed informed consent/authorization obtain prior conduct study specific screening procedure . No prior chemotherapy advance pancreatic cancer Patient must measurable disease Use effective mean contraception ( men woman ) subject childbearing potential Obstructive jaundice must relieve inclusion Adequate hepatic , renal , bone marrow function : leukocyte &gt; = 3,000/uL , absolute neutrophil count &gt; = 1,500/uL , platelet &gt; = 100,000/uL , total bilirubin &lt; = 1.5 X institutional upper limit normal ( ULN ) , AST ( SGOT ) /ALT ( SGPT ) &lt; = 2.5 X institutional ULN , creatinine &lt; = 1.5 mg/dL Previous chemotherapy pancreatic cancer . Patients recurrent disease within 6 month pancreaticoduodenectomy receive adjuvant therapy within 6 month disease recurrence . Uncontrolled intercurrent illness include : Active infection Cardiovascular : New York Heart Association ( NYHA ) grade II great congestive heart failure , unstable angina pectoris , cardiac arrhythmia well control medication , myocardial infarction within previous 6 month , blood pressure &gt; 150/100 mmHg Clinically significant peripheral vascular disease History stroke within previous 6 month Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 0 , anticipation need major surgical procedure course study . Minor surgical procedure , fine needle aspiration core biopsy within 7 day prior Day 0 Urine protein : creatinine ratio &gt; 1.0 screen History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior Day 0 Serious , nonhealing wound , ulcer , bone fracture Patients know brain metastasis exclude clinical trial poor prognosis often develop progressive neurological dysfunction would confound evaluation neurological adverse event . A computed tomography ( CT ) scan brain need eligibility do patient present symptom suggestive brain metastasis . Patients may receive investigational agent , participate investigational drug study within 28 day precede start study treatment . The teratogenic potential combination currently unknown . Women pregnant lactating exclude . History malignancy last 5 year , except patient prior history situ cancer basal squamous cell skin cancer . Peripheral neuropathy &gt; grade 1 Psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>unresectable pancreatic cancer</keyword>
	<keyword>metastatic pancreatic cancer</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>1st line treatment</keyword>
	<keyword>first line treatment</keyword>
	<keyword>locally advanced ( unresectable ) pancreatic cancer</keyword>
</DOC>